TUSTIN, Calif.--(BW HealthWire)--Dec. 4, 1997--Techniclone Corporation (Nasdaq:TCLN) today announced Rockell N. Hankin, Chief Executive of Hankin & Co., a management consulting firm, and Hankin Investment Banking has joined Techniclone's Board of Directors. This increases the number of board members to six.
Mr. Hankin has extensive leadership experience with publicly traded companies. He is the Chairman of the Board of House of Fabrics and serves on the board of directors of Alpha Microsystems, Quidel Corporation, a biotechnology company and Semtech Corporation as well as several privately held companies. His previous board experience includes DDL Electronics, Inc., Nichols Institute before it merged with Corning in 1994, La Victoria Foods, Orthomedics, a medical products manufacturer, and VTEK, prior to their being sold. Additionally, Mr. Hankin has also served on the National Board of Advisors of The Executive Committee, an organization of Chief Executive Officers.
In addition to his roles at Hankin & Co., and Hankin Investment Banking, Mr. Hankin is a faculty member of the Anderson Graduate School of Management at the University of California, Los Angeles. Previously, Mr. Hankin served as the Managing Partner of the Warner Center Los Angeles office of Price Waterhouse, LLP. He graduated cum laude with a Bachelor of Science degree in Accounting from UCLA, and received his Bachelor of Laws Degree from the Blackstone School of Law. He is a Certified Public Accountant and Member of the Bar.
"We are pleased to have someone of Mr. Hankin's caliber join Techniclone's Board of Directors," said Lon H. Stone, President, CEO and Chairman. "His expertise in business strategy and finance will be valuable as we move forward."
Techniclone Corporation is a rapidly growing biotechnology company engaged in the research and development of therapeutics for the treatment of cancer. The company is a world leader in collateral targeting, a powerful new approach to destroying cancerous tumors without attaching to surrounding healthy tissue. The company's lead collateral targeting technologies include: Tumor Necrosis Therapy (TNT), Vascular Targeting Agents (VTAs) and Vasopermeation Enhancement Agents (VEAs). Techniclone's most advanced drug development program is LYM-1 (Oncolym(TM)), which is being investigated for the treatment of non-Hodgkin's B-cell lymphoma.
For additional company and product pipeline information, please visit Techniclone Corporation's web site at techniclone.com -0-
Any statements released by Techniclone that are forward looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties which may affect the Company's business and prospects, including economic, competitive, government, technological and other factors discussed in the Company's filings with the Securities and Exchange Commission.
CONTACT:
Techniclone Corporation
William (Bix) Moding
Chief Financial Officer
714/508-6040
or
Jennifer C. Gianola
Director, Corporate Communications
714/508-6034
KEYWORD: CALIFORNIA
BW1038 DEC 04,1997
|
